Ambu A/S (OTCMKTS:AMBBY) Sees Strong Trading Volume – Here’s What Happened

Ambu A/S Unsponsored ADR (OTCMKTS:AMBBY – Get Free Report) shares saw strong trading volume on Friday. 4,600 shares traded hands during mid-day trading, an increase of 602% from the average daily volume of 655 shares. The stock last traded at $13.30 and had previously closed at $13.00.

Analysts Set New Price Targets

Separately, UBS Group downgraded Ambu A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 15th. One investment analyst has rated the stock with a Hold rating. Based on data from MarketBeat, the company currently has a consensus rating of “Hold”.

Check Out Our Latest Stock Report on Ambu A/S

Ambu A/S Stock Performance

The stock has a 50-day moving average of $11.36 and a 200 day moving average of $10.97. The stock has a market cap of $3.13 billion, a PE ratio of 35.95 and a beta of 0.86. The company has a quick ratio of 1.69, a current ratio of 2.77 and a debt-to-equity ratio of 0.08.

Ambu A/S (OTCMKTS:AMBBY – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported $0.14 earnings per share (EPS) for the quarter. Ambu A/S had a return on equity of 10.47% and a net margin of 9.90%.

Ambu A/S Company Profile

(Get Free Report)

Ambu A/S is a Danish medical-device company that develops, manufactures and markets equipment for hospitals and other healthcare settings. Its products are used in anesthesia, patient monitoring and diagnostics, and endoscopy. The company’s portfolio includes ventilation and resuscitation devices, electrodes and single-use endoscopes. Ambu is also known for the Ambu bag, a self-inflating resuscitation bag introduced in the 1950s. Founded in Denmark in 1937, Ambu serves healthcare professionals in markets around the world.

Read More

Receive News & Ratings for Ambu A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ambu A/S and related companies with MarketBeat.com's FREE daily email newsletter.